Rapid Health Technology Assessment Abemaciclib in the Treatment of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Objective:To evaluate the efficacy,safety and economy of Abemaciclib(ABE)in the treatment of hormone receptor posi-tive(HR+)/human epidermal growth factor receptor-2-negative(HER2-)metastatic/advanced breast cancer.Methods:By searching CNKI,Wanfang,PubMed,Embase and other Chinese and English databases,two reviewers were selected and analyzed according to in-clusion and exclusion criteria respectively.Results:A total of 2 Health Technology assessment(HTA)reports,12 SR/meta-analyses,and 7 economic studies were included.In the treatment of HR+/HER2-advanced or metastatic breast cancer,in terms of efficacy and safety,compared with ET,ABE combined with endocrine therapy(ET)can significantly improve patients'progression-free survival(PFS)and tumor objective response rate(ORR),but increase the risk of adverse reactions such as blood system,gastrointestinal tract and venous thrombosis,and compared with the similar drugs Palbociclib(PAL),Ribociclib(RIB),the efficacy and safety is compara-ble.In terms of economics,most results suggest that ABE+ET does not have a cost-effectiveness advantage over ET alone or other drugs of the same class.Conclusion:ABE has a good efficacy and acceptable safety profile in HR+/HER2-advanced or metastatic breast cancer,but no significant economic advantages.
AbemaciclibAdvanced/metastatic breast cancerRapid health technology assessmentCost-effectiveness
万方数据
维普
